| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
|
Lancet
|
2006
|
5.07
|
|
2
|
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
|
Blood
|
2008
|
2.68
|
|
3
|
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
|
J Clin Oncol
|
2007
|
2.14
|
|
4
|
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
|
J Clin Oncol
|
2010
|
1.76
|
|
5
|
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
|
Blood
|
2007
|
1.47
|
|
6
|
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
|
Blood
|
2004
|
1.37
|
|
7
|
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
|
Hematol J
|
2004
|
1.03
|
|
8
|
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
|
Cancer
|
2008
|
1.03
|
|
9
|
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
|
Blood
|
2005
|
1.01
|
|
10
|
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
|
Cancer
|
2005
|
0.91
|
|
11
|
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy.
|
J Clin Oncol
|
2003
|
0.89
|
|
12
|
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
|
Eur J Haematol
|
2010
|
0.86
|
|
13
|
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
|
Eur J Haematol
|
2005
|
0.82
|
|
14
|
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
0.82
|
|
15
|
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
|
Eur J Haematol
|
2006
|
0.81
|
|
16
|
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
|
Cancer
|
2007
|
0.81
|
|
17
|
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.
|
Tumori
|
2013
|
0.80
|
|
18
|
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
|
Eur J Haematol
|
2007
|
0.79
|
|
19
|
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
|
Clin Lymphoma Myeloma
|
2009
|
0.79
|
|
20
|
Update on recent developments for patients with newly diagnosed multiple myeloma.
|
Ann N Y Acad Sci
|
2008
|
0.78
|
|
21
|
Treatment of newly diagnosed multiple myeloma.
|
Curr Hematol Malig Rep
|
2008
|
0.75
|
|
22
|
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
|
Hematol J
|
2004
|
0.75
|